Novel display system for antibody affinity maturation
Novel display system for antibody affinity maturation
批准号:
6882322
负责人:
DAVID S WILSON
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-01-01 至 2005-06-30
关键词:
DNA binding proteinSDS polyacrylamide gel electrophoresisantigen antibody reactionantiviral antibodybiotechnologyenzyme linked immunosorbent assayhybrid antibodyimmunogeneticsimmunoglobulin structuremonoclonal antibodypeptide librarypoint mutationprotein protein interactionprotein quantitation /detectionprotein sequencetechnology /technique developmenttransfection /expression vectorwestern blottings
中文摘要
描述(由申请人提供):抗体作为治疗剂的使用在过去几年中获得了越来越多的认可,目前有18种fda批准的单克隆抗体疗法。与传统的小分子方法相比,基于抗体的治疗方法的主要优点是:开发时间更短;降低毒性;破坏蛋白质之间相互作用的能力。这种方法的成功之处是开发了降低给病人的抗体免疫原性的方法。这种方法通常依赖于筛选大量人或人源化抗体候选物的能力。显示系统提供了最有效的机制来识别这些抗体库中罕见的、高亲和力的成员。然而,目前可用的展示系统(噬菌体展示、核糖体展示和酵母展示)的有效性受到库成员之间强烈的选择偏差的限制,这些选择偏差不能转化为改进的抗体亲和力。这些偏差包括重链和轻链表达水平和/或分泌效率的差异,scFv的稳定性/二聚化的差异,以及贪婪效应的差异。这项资助的目的是开发一种新的显示系统,克服所有这些偏见,并提供一种强大而有效的方法来识别针对几乎任何治疗靶点的高亲和力和特异性的人类或人源化抗体。
英文摘要
DESCRIPTION (provided by applicant): The use of antibodies as therapeutic agents has gained increasing acceptance over the last several years, and there are currently 18 FDA-approved monoclonal antibody therapies. The main advantages of antibody-based therapy over traditional, small molecule approaches are: more rapid development times; lower toxicity; ability to disrupt protein-protein interactions. The success of this approach has been the development of methods for reducing the immunogenicity of antibodies administered to patients. Such methods generally rely on the ability to screen through large numbers of human or humanized antibody candidates. Display systems offer the most efficient mechanism for identifying rare, high affinity members of such antibody libraries. The effectiveness of currently available display systems (phage display, ribosome display, and yeast display), however, is limited by strong selection biases between library members that do not translate to improved antibody affinity. Such biases include differences in heavy and light chain expression levels and/or secretion efficiency, differences in stability/dimerization of scFv's, and differences from avidity effects. The object of this grant is to develop a novel display system that overcomes all of these biases and provides a robust and efficient method for identifying high affinity and specificity human or humanized antibodies against nearly any therapeutic target.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mulitplexed protein measurement by real-time immuno-PCR
-
批准号:6788946
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2004
-
负责人:DAVID S WILSON
-
依托单位:
Antagonism of PAMP, a potent angiogenic factor
-
批准号:6831751
-
项目类别:
-
资助金额:$12.96万
-
财政年份:2004
-
负责人:DAVID S WILSON
-
依托单位: